Avidity Partners Management LP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Avidity Partners Management LP reported 84 stock positions worth $2.4 billion. Its top holding was Intuitive Surgical (ISRG) at 4.6% of the portfolio, followed by Boston Scientific (BSX, 3.8%) and Natera (NTRA, 3.5%). Compared with Q1 2024, it opened 18 new positions, sold out of 20, added to 28 and reduced 24. The biggest buy was Intuitive Surgical (ISRG, shares +8%) and the biggest sale an exit from Fusion Pharmaceuticals (FUSN).
- Most Recent 13F
- Q2 2026
- Location
- DALLAS, TX
- CIK
- 0001791827
- Portfolio Value
- $2.4B (Q2 2024)
- SEC Filing
- 0001791827-24-000007 ↗ filed Aug 14, 2024
Holdings Value
Holdings 84 stocks · $2.4B
| ISRG Intuitive Surgical Inc. | 4.63% | 245,000 | $109.0M | Add +8.4% |
| BSX Boston Scientific Corp. | 3.83% | 1,170,100 | $90.1M | Reduce -40.2% |
| NTRA Natera Inc. | 3.53% | 766,500 | $83.0M | Reduce -4.6% |
| ARVN Arvinas Inc. | 3.38% | 2,987,845 | $79.5M | Add +0.1% |
| ACHC Acadia Healthcare Co. Inc. | 3.21% | 1,120,000 | $75.6M | Add +11.4% |
| DNTH Dianthus Therapeutics Inc. | 3.21% | 2,917,231 | $75.5M | Add +7.3% |
| SNDX Syndax Pharmaceuticals Inc. | 2.91% | 3,335,000 | $68.5M | Add +38.2% |
| NBIX Neurocrine Biosciences Inc. | 2.87% | 491,000 | $67.6M | Reduce -8.5% |
| AVTR Avantor Inc. | 2.78% | 3,086,000 | $65.4M | Add +14.5% |
| CI The Cigna Group | 2.59% | 184,500 | $61.0M | No change |
| JAZZ Jazz Pharmaceuticals PLC | 2.47% | 544,500 | $58.1M | Reduce -6.8% |
| ALNY Alnylam Pharmaceuticals Inc. | 2.29% | 222,000 | $53.9M | Reduce -8.6% |
| REGN Regeneron Pharmaceuticals | 2.14% | 48,000 | $50.4M | Reduce -29.4% |
| ILMN Illumina Inc. | 2.12% | 478,000 | $49.9M | Add +3.0% |
| THC Tenet Healthcare Corp. | 2.10% | 372,000 | $49.5M | Reduce -38.1% |
| ABBV Abbvie Inc. | 2.02% | 277,800 | $47.6M | Add +22.4% |
| TMO Thermo Fisher Scientific Inc. | 1.88% | 80,000 | $44.2M | Add +118.6% |
| GPCR Structure Therapeutics Inc. | 1.79% | 1,075,000 | $42.2M | Add +24.4% |
| BPMC Blueprint Medicines Corp. | 1.75% | 383,000 | $41.3M | Reduce -10.1% |
| CGON CG Oncology Inc. | 1.74% | 1,296,225 | $40.9M | Reduce -10.9% |
| MRK Merck & Co. Inc. | 1.71% | 325,000 | $40.2M | Reduce -35.3% |
| RARE Ultragenyx Pharmaceutical Inc. | 1.68% | 960,000 | $39.5M | Add +2.8% |
| IDYA Ideaya Biosciences Inc. | 1.67% | 1,117,000 | $39.2M | Add +39.7% |
| DHR Danaher Corp. | 1.59% | 150,000 | $37.5M | Add +4.3% |
| JANX Janux Therapeutics Inc. | 1.50% | 840,219 | $35.2M | Add +118.7% |
| UTHR United Therapeutics Corp. | 1.49% | 110,000 | $35.0M | Reduce -49.3% |
| INCY Incyte Corp. | 1.36% | 529,000 | $32.1M | New |
| SGRY Surgery Partners Inc. | 1.32% | 1,306,477 | $31.1M | Reduce -9.6% |
| CATX Perspective Therapeutics Inc. | 1.29% | 3,037,668 | $30.3M | New |
| AXSM Axsome Therapeutics Inc. | 1.29% | 376,000 | $30.3M | Reduce -12.8% |
| XENE Xenon Pharmaceuticals Inc. | 1.25% | 754,000 | $29.4M | Add +6.2% |
| DXCM Dexcom Inc. | 1.25% | 259,000 | $29.4M | Add +46.4% |
| RVMD Revolution Medicines Inc. | 1.25% | 755,000 | $29.3M | Add +18.9% |
| INSM Insmed Inc. | 1.22% | 430,000 | $28.8M | New |
| ITCI Intra-Cellular Therapies Inc. | 1.16% | 400,000 | $27.4M | Reduce -33.3% |
| CGEM Cullinan Therapeutics Inc. | 1.16% | 1,559,826 | $27.2M | New |
| GKOS Glaukos Corp. | 1.13% | 224,000 | $26.5M | No change |
| NGNE Neurogene Inc. | 1.13% | 727,537 | $26.5M | Add +56.4% |
| ARGX Argenx SE - ADR | 1.11% | 60,500 | $26.0M | New |
| MIRM Mirum Pharmaceuticals Inc. | 1.06% | 731,104 | $25.0M | Reduce -36.0% |
| ESTA Establishment Labs Holdings | 1.03% | 531,000 | $24.1M | Add +136.0% |
| IMVT Immunovant Inc. | 1.02% | 908,000 | $24.0M | Add +79.8% |
| RCKT Rocket Pharmaceuticals Inc. | 1.01% | 1,100,000 | $23.7M | Add +7.3% |
| LNTH Lantheus Holdings Inc. | 0.99% | 290,000 | $23.3M | Reduce -39.6% |
| PCVX Vaxcyte Inc. | 0.91% | 284,000 | $21.4M | No change |
| APGE Apogee Therapeutics Inc. | 0.81% | 487,000 | $19.2M | Add +26.5% |
| JSPR Jasper Therapeutics Inc. | 0.75% | 782,000 | $17.8M | Add +2.9% |
| NMRA Neumora Therapeutics Inc. | 0.75% | 1,800,000 | $17.7M | No change |
| LEGN Legend Biotech Corp.-ADR | 0.75% | 398,000 | $17.6M | Reduce -40.5% |
| GILD Gilead Sciences Inc. | 0.74% | 255,000 | $17.5M | New |
| PHAT Phathom Pharmaceuticals Inc. | 0.71% | 1,620,000 | $16.7M | Reduce -6.6% |
| AZN Astrazeneca PLC-Spons ADR | 0.68% | 205,000 | $16.0M | Add +28.1% |
| KROS Keros Therapeutics Inc. | 0.67% | 343,200 | $15.7M | Add +63.7% |
| BHVN Biohaven Ltd. | 0.66% | 450,000 | $15.6M | Add +500.0% |
| SNY Sanofi-ADR | 0.65% | 315,000 | $15.3M | New |
| RGNX Regenxbio Inc. | 0.65% | 1,300,064 | $15.2M | No change |
| CNTX Context Therapeutics Inc. | 0.63% | 7,419,355 | $14.9M | New |
| EXAS Exact Sciences Corp. | 0.61% | 338,500 | $14.3M | New |
| PRVA Privia Health Group Inc. | 0.56% | 764,200 | $13.3M | No change |
| NAMS Newamsterdam Pharma Co. NV | 0.46% | 559,300 | $10.7M | Add +17.8% |
| IMNM Immunome Inc. | 0.45% | 873,891 | $10.6M | No change |
| IMUX Immunic Inc. | 0.42% | 8,902,972 | $9.9M | No change |
| CRBP Corbus Pharmaceuticals Holdi | 0.41% | 215,600 | $9.8M | New |
| CYBIN INC | 0.40% | 34,884,000 | $9.5M | No change |
| SYRS Syros Pharmaceuticals Inc. | 0.37% | 1,673,538 | $8.6M | No change |
| COGT Cogent Biosciences Inc. | 0.36% | 1,000,706 | $8.4M | Add +124.5% |
| IMCR Immunocore Holdings PLC-ADR | 0.29% | 200,000 | $6.8M | Reduce -30.2% |
| TYRA Tyra Biosciences Inc. | 0.25% | 373,000 | $6.0M | New |
| PATH Uipath Inc. Class A | 0.20% | 362,000 | $4.6M | New |
| SYRE Spyre Therapeutics Inc. | 0.19% | 195,000 | $4.6M | New |
| IMTX Immatics NV | 0.19% | 393,100 | $4.6M | New |
| IONS Ionis Pharmaceuticals Inc. | 0.19% | 93,000 | $4.4M | Reduce -28.5% |
| ARCA BIOPHARMA INC | 0.16% | 1,000,000 | $3.8M | New |
| EDIT Editas Medicine Inc. | 0.16% | 816,000 | $3.8M | New |
| NTLA Intellia Therapeutics Inc. | 0.16% | 170,000 | $3.8M | New |
| COLL Collegium Pharmaceutical Inc. | 0.16% | 117,000 | $3.8M | Reduce -67.6% |
| PRME Prime Medicine Inc. | 0.15% | 694,000 | $3.6M | Reduce -65.1% |
| ACIU Ac Immune SA | 0.14% | 825,000 | $3.3M | Reduce -81.5% |
| KEZAR LIFE SCIENCES INC | 0.13% | 5,026,000 | $3.0M | No change |
| SCYX Scynexis Inc. | 0.12% | 1,448,728 | $2.9M | No change |
| KPTI Karyopharm Therapeutics Inc. | 0.07% | 2,018,500 | $1.8M | Reduce -75.7% |
| WVE Wave Life Sciences Ltd. | 0.07% | 350,000 | $1.7M | New |
| HYPR Hyperfine Inc. | 0.04% | 1,188,178 | $1.0M | No change |
| CMAXQ Caremax Inc. | 0.00% | 21,200 | $59K | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $2K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | 12,136 | $2K | Reduce -86.5% |
Total filed on the 13F, all lines: $2.4B.
Portfolio Sells Q1 2024 → Q2 2024
| FUSN Fusion Pharmaceuticals Inc. | Sold out | 0.00% | −4.93 |
| ALGN Align Technology Inc. | Sold out | 0.00% | −2.20 |
| LLY Eli Lilly & Co. | Sold out | 0.00% | −1.94 |
| ALPN Alpine Immune Sciences Inc. | Sold out | 0.00% | −1.66 |
| CVS CVS Health Corp. | Sold out | 0.00% | −1.54 |
| CRBU Caribou Biosciences Inc. | Sold out | 0.00% | −1.06 |
| BSX Boston Scientific Corp. | Reduce -40.2% | 3.83% | −0.93 |
| MRK Merck & Co. Inc. | Reduce -35.3% | 1.71% | −0.64 |
| MCK McKesson Corp. | Sold out | 0.00% | −0.64 |
| VERA Vera Therapeutics Inc. | Sold out | 0.00% | −0.59 |
| LEGN Legend Biotech Corp.-ADR | Reduce -40.5% | 0.75% | −0.58 |
| CGON CG Oncology Inc. | Reduce -10.9% | 1.74% | −0.53 |
| ATXS Astria Therapeutics Inc. | Sold out | 0.00% | −0.49 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −0.41 |
| RDNT Radnet Inc. | Sold out | 0.00% | −0.41 |
| ACAD Acadia Pharmaceuticals Inc. | Sold out | 0.00% | −0.39 |
| IMCR Immunocore Holdings PLC-ADR | Reduce -30.2% | 0.29% | −0.37 |
| KPTI Karyopharm Therapeutics Inc. | Reduce -75.7% | 0.07% | −0.37 |
| PRME Prime Medicine Inc. | Reduce -65.1% | 0.15% | −0.34 |
| COLL Collegium Pharmaceutical Inc. | Reduce -67.6% | 0.16% | −0.34 |
| ACIU Ac Immune SA | Reduce -81.5% | 0.14% | −0.33 |
| ITCI Intra-Cellular Therapies Inc. | Reduce -33.3% | 1.16% | −0.31 |
| UTHR United Therapeutics Corp. | Reduce -49.3% | 1.49% | −0.28 |
| SGRY Surgery Partners Inc. | Reduce -9.6% | 1.32% | −0.21 |
| REGN Regeneron Pharmaceuticals | Reduce -29.4% | 2.14% | −0.18 |
| IPSC Century Therapeutics Inc. | Sold out | 0.00% | −0.18 |
| KYTX Kyverna Therapeutics Inc. | Sold out | 0.00% | −0.18 |
| EBS Emergent Biosolutions Inc. | Sold out | 0.00% | −0.17 |
| THC Tenet Healthcare Corp. | Reduce -38.1% | 2.10% | −0.14 |
| ANTX AN2 Therapeutics Inc. | Sold out | 0.00% | −0.13 |
| DNA Ginkgo Bioworks Holdings Inc. | Sold out | 0.00% | −0.12 |
| XFOR X4 Pharmaceuticals Inc. | Sold out | 0.00% | −0.12 |
| PACB Pacific Biosciences of Calif | Sold out | 0.00% | −0.09 |
| LNTH Lantheus Holdings Inc. | Reduce -39.6% | 0.99% | −0.07 |
| KOD Kodiak Sciences Inc. | Sold out | 0.00% | −0.06 |
| JAZZ Jazz Pharmaceuticals PLC | Reduce -6.8% | 2.47% | −0.03 |
| IONS Ionis Pharmaceuticals Inc. | Reduce -28.5% | 0.19% | −0.01 |
| MIRM Mirum Pharmaceuticals Inc. | Reduce -36.0% | 1.06% | +0.04 |
| PHAT Phathom Pharmaceuticals Inc. | Reduce -6.6% | 0.71% | +0.05 |
| AXSM Axsome Therapeutics Inc. | Reduce -12.8% | 1.29% | +0.06 |
| NBIX Neurocrine Biosciences Inc. | Reduce -8.5% | 2.87% | +0.24 |
| BPMC Blueprint Medicines Corp. | Reduce -10.1% | 1.75% | +0.32 |
| NTRA Natera Inc. | Reduce -4.6% | 3.53% | +0.92 |
| ALNY Alnylam Pharmaceuticals Inc. | Reduce -8.6% | 2.29% | +1.00 |
Portfolio Buys Q1 2024 → Q2 2024
| ISRG Intuitive Surgical Inc. | Add +8.4% | 4.63% | +1.43 |
| INCY Incyte Corp. | New | 1.36% | +1.36 |
| CATX Perspective Therapeutics Inc. | New | 1.29% | +1.29 |
| INSM Insmed Inc. | New | 1.22% | +1.22 |
| CGEM Cullinan Therapeutics Inc. | New | 1.16% | +1.16 |
| TMO Thermo Fisher Scientific Inc. | Add +118.6% | 1.88% | +1.12 |
| ARGX Argenx SE - ADR | New | 1.11% | +1.11 |
| JANX Janux Therapeutics Inc. | Add +118.7% | 1.50% | +0.98 |
| SNDX Syndax Pharmaceuticals Inc. | Add +38.2% | 2.91% | +0.87 |
| GILD Gilead Sciences Inc. | New | 0.74% | +0.74 |
| SNY Sanofi-ADR | New | 0.65% | +0.65 |
| CNTX Context Therapeutics Inc. | New | 0.63% | +0.63 |
| ESTA Establishment Labs Holdings | Add +136.0% | 1.03% | +0.62 |
| EXAS Exact Sciences Corp. | New | 0.61% | +0.61 |
| ABBV Abbvie Inc. | Add +22.4% | 2.02% | +0.56 |
| BHVN Biohaven Ltd. | Add +500.0% | 0.66% | +0.52 |
| RVMD Revolution Medicines Inc. | Add +18.9% | 1.25% | +0.52 |
| GPCR Structure Therapeutics Inc. | Add +24.4% | 1.79% | +0.48 |
| IMVT Immunovant Inc. | Add +79.8% | 1.02% | +0.44 |
| IDYA Ideaya Biosciences Inc. | Add +39.7% | 1.67% | +0.42 |
| CRBP Corbus Pharmaceuticals Holdi | New | 0.41% | +0.41 |
| ACHC Acadia Healthcare Co. Inc. | Add +11.4% | 3.21% | +0.38 |
| DXCM Dexcom Inc. | Add +46.4% | 1.25% | +0.38 |
| AVTR Avantor Inc. | Add +14.5% | 2.78% | +0.33 |
| DHR Danaher Corp. | Add +4.3% | 1.59% | +0.32 |
| DNTH Dianthus Therapeutics Inc. | Add +7.3% | 3.21% | +0.31 |
| AZN Astrazeneca PLC-Spons ADR | Add +28.1% | 0.68% | +0.29 |
| NGNE Neurogene Inc. | Add +56.4% | 1.13% | +0.28 |
| TYRA Tyra Biosciences Inc. | New | 0.25% | +0.25 |
| COGT Cogent Biosciences Inc. | Add +124.5% | 0.36% | +0.25 |
| PATH Uipath Inc. Class A | New | 0.20% | +0.20 |
| SYRE Spyre Therapeutics Inc. | New | 0.19% | +0.19 |
| IMTX Immatics NV | New | 0.19% | +0.19 |
| KROS Keros Therapeutics Inc. | Add +63.7% | 0.67% | +0.17 |
| XENE Xenon Pharmaceuticals Inc. | Add +6.2% | 1.25% | +0.16 |
| ARCA BIOPHARMA INC | New | 0.16% | +0.16 |
| EDIT Editas Medicine Inc. | New | 0.16% | +0.16 |
| NTLA Intellia Therapeutics Inc. | New | 0.16% | +0.16 |
| RARE Ultragenyx Pharmaceutical Inc. | Add +2.8% | 1.68% | +0.13 |
| WVE Wave Life Sciences Ltd. | New | 0.07% | +0.07 |
| NAMS Newamsterdam Pharma Co. NV | Add +17.8% | 0.46% | +0.06 |
| RCKT Rocket Pharmaceuticals Inc. | Add +7.3% | 1.01% | +0.02 |
| JSPR Jasper Therapeutics Inc. | Add +2.9% | 0.75% | −0.04 |
| APGE Apogee Therapeutics Inc. | Add +26.5% | 0.81% | −0.09 |
| ILMN Illumina Inc. | Add +3.0% | 2.12% | −0.15 |
| ARVN Arvinas Inc. | Add +0.1% | 3.38% | −1.00 |
Options Activity Q1 2024 → Q2 2024
| ITCI Intra-Cellular Therapies Inc. | call | Sold out | 600,000 | $239.5Mbefore exit |
| CYTK Cytokinetics Inc. | call | Sold out | 600,000 | $42.1Mbefore exit |
| GPCR Structure Therapeutics Inc. | call | Sold out | 150,000 | $6.4Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q1 2024 → Q2 2024
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | Reduce -86.5% | 12,136 | $2K |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 45 | $624.4M | DNTH, CGON, ORKA, JBIO, ELVN |
| Q1 2026Amended | 45 | $493.8M | DNTH, CGON, ORKA, CATX, JBIO |
| Q4 2025 | 39 | $346.7M | DNTH, CGON, JBIO, ORKA, TEVA |
| Q3 2025 | 43 | $439.4M | DNTH, CGON, MDT, BSX, ORKA |
| Q2 2025 | 55 | $498.8M | CGON, BSX, NTRA, DNTH, EXAS |
| Q1 2025 | 63 | $484.9M | BSX, DNTH, UNH, CGON, HUM |
| Q4 2024 | 61 | $1.0B | DNTH, BSX, JANX, NTRA, EXAS |
| Q3 2024 | 81 | $2.0B | BSX, DNTH, ISRG, NTRA, CGON |
| Q2 2024 | 84 | $2.4B | ISRG, BSX, NTRA, ARVN, ACHC |
| Q1 2024 | 86 | $2.8B | FUSN, BSX, ARVN, ISRG, DNTH |